Understanding Measles Rash

Measles, also called rubeola, is a highly contagious viral infection caused by the measles virus (paramyxovirus) that presents with a characteristic maculopapular rash preceded by high fever and the "three Cs" of prodromal symptoms: cough, coryza (runny nose), and conjunctivitis. The rash is considered one of the most distinctive childhood exanthems, making measles relatively easy to diagnose clinically. While measles has largely been controlled in developed countries through vaccination, the disease remains prevalent in under-vaccinated populations and continues to cause significant morbidity and mortality worldwide. Understanding the clinical presentation of measles, risk factors for severe disease, and appropriate management is important for healthcare providers encountering suspected cases.

Epidemiology and Virology

Measles is caused by a single-stranded RNA virus of the paramyxovirus genus. The virus is highly contagious, spreading through respiratory droplets with an incubation period of 10-14 days. Prior to the introduction of measles vaccine, measles was nearly universal in childhood. Introduction of the live attenuated measles vaccine has resulted in dramatic decreases in measles incidence in well-vaccinated populations. However, periodic epidemics occur in communities with declining vaccination coverage, and measles remains endemic in many parts of the world. Vaccination failures and disease in immunocompromised individuals can occur. Most measles cases now occur in unvaccinated or inadequately vaccinated individuals. Congenital measles can occur following maternal infection during pregnancy.

Clinical Presentation

Measles typically begins with an acute prodromal phase characterized by fever (often reaching 40°C/104°F), malaise, anorexia, and the pathognomonic "three Cs": cough, coryza, and conjunctivitis. Koplik spots—small white spots on the buccal mucosa opposite the molars—appear 2-3 days into illness and are virtually pathognomonic for measles, appearing before the rash develops. The characteristic rash appears 3-4 days after fever onset, beginning on the face and hairline, then spreading rapidly downward to involve the trunk and extremities over 2-3 days. The rash consists of confluent, maculopapular lesions that are typically blanching initially but may become non-blanching. The rash may appear on the palms and soles. During the rash phase, fever intensifies and systemic symptoms may worsen before improving as the rash fades.

Complications and Serious Disease

While measles is often thought of as a mild childhood exanthem, serious complications occur in a significant minority of cases. Otitis media occurs in 5-15% of cases. Diarrhea occurs in 8% of cases. Encephalitis, one of the most serious complications, occurs in 0.1-0.2% of cases with significant mortality and neurological sequelae. Subacute sclerosing panencephalitis (SSPE), a fatal progressive neurological disease, occurs in approximately 1 in 10,000 measles infections, typically manifesting years after initial infection. Pneumonia develops in 1-5% of immunocompetent children and higher percentages in immunocompromised hosts. Secondary bacterial superinfection may develop. Measles can be particularly severe in infants under 1 year, in immunocompromised individuals, and in populations with malnutrition or vitamin A deficiency.

Diagnosis and Testing

Diagnosis of measles is primarily clinical based on the characteristic presentation of prodromal symptoms, Koplik spots, and distinctive rash. Serological testing for measles-specific IgM antibodies confirms acute infection. PCR testing detecting measles RNA can identify the virus. Viral culture is rarely performed. The characteristic clinical presentation is usually sufficient for diagnosis. Given the serious public health implications of measles (disease is reportable), laboratory confirmation should be pursued when suspected.

Management and Treatment

Management of measles is supportive. No specific antiviral therapy is available. Treatment focuses on fever management, hydration, nutritional support, and monitoring for complications. Vitamin A supplementation is recommended by the WHO for measles cases and is associated with reduced morbidity and mortality, particularly in children under 5 years and those with malnutrition. Antibiotics should be reserved for documented bacterial superinfections. Patients should be isolated from others until 4 days after rash onset. Vaccination status and contacts should be documented; unvaccinated contacts should receive measles post-exposure prophylaxis if within 72 hours of exposure.

Prevention and Vaccination

Measles vaccination has been remarkably effective in preventing disease in vaccinated populations. The MMR (measles-mumps-rubella) vaccine is highly efficacious, with approximately 95% effectiveness following two doses. Wide-scale vaccination has resulted in dramatic reductions in measles incidence in well-vaccinated populations. However, maintenance of high vaccination rates (typically >95% of population) is necessary to prevent community spread and periodic epidemics. Healthcare providers should confirm vaccination status and ensure appropriate vaccination in all eligible children.

Frequently Asked Questions

How serious is measles? Measles can cause serious complications including pneumonia and encephalitis, though most cases are self-limited.

When will the rash appear? The rash typically appears 3-4 days after fever onset, once Koplik spots have appeared.

Is my child contagious? Yes. Measles is highly contagious from the prodromal phase until 4 days after rash onset.

Will vaccination prevent measles? MMR vaccination is highly effective (95% after two doses) at preventing measles.

Can vaccinated people get measles? Rarely. Vaccine failures occur in 5% of vaccinated individuals, and breakthrough infections can occur in immunocompromised hosts.

References

  1. Paller AS, Mancini AJ. Hurwitz Clinical Pediatric Dermatology. 5th ed. Elsevier; 2016.
  2. Habif TP. Clinical Dermatology: A Color Guide to Diagnosis and Therapy. 6th ed. Elsevier; 2016.
  3. Gershon AA. Measles (Rubeola). Pediatr Rev. 1990;12(4):91-105.
  4. Black FL. Measles. In: Arvin AM, et al., eds. Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis. Cambridge University Press; 2007.
  5. Moss WJ, Griffin DE. Global measles elimination. Nat Rev Microbiol. 2006;4(12):900-908.
  6. Steyn N, Muloiwa R, Hunter A, et al. Severe measles pneumonia in HIV-infected and HIV-uninfected children. Pediatr Infect Dis J. 2017;36(6):614-616.
  7. World Health Organization. Measles Fact Sheets. Updated 2019.
  8. Bellini WJ, Helfand RF. The challenges and strategies for global elimination of measles. Clin Infect Dis. 2003;37(Suppl 1):S47-S52.